Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0DFJAE)
| ADC Name |
KY-0301
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
KY-0301; RB-601?
Click to Show/Hide
|
|||||
| Organization |
Keyi Pharmaceutical (Originator);Radiance
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
EGFR/c-Met bispecific nanobody
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Site-specific
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Colorectal cancer |
1 Trials
|
|||||
| Lung cancer |
1 Trials
|